WPA
CRSP icon

West Paces Advisors’s CRISPR Therapeutics CRSP Stock Holding History

West Paces Advisors’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.35K Buy
+153
New +$8.06K ﹤0.01% 398
2025
Q2 		– Sell
-85
Closed -$2.89K – 288
2025
Q1 		$2.89K Hold
85
– – ﹤0.01% 415
2024
Q4 		$3.35K Hold
85
– – ﹤0.01% 409
2024
Q3 		$3.99K Hold
85
– – ﹤0.01% 395
2024
Q2 		$4.59K Hold
85
– – ﹤0.01% 394
2024
Q1 		$5.79K Hold
85
– – ﹤0.01% 395
2023
Q4 		$5.32K Hold
85
– – ﹤0.01% 405
2023
Q3 		$3.86K Hold
85
– – ﹤0.01% 403
2023
Q2 		$4.77K Hold
85
– – ﹤0.01% 424
2023
Q1 		$3.85K Hold
85
– – ﹤0.01% 441
2022
Q4 		$3.46K Buy
85
+50
+143% +$2.65K ﹤0.01% 415
2022
Q3 		$2.29K Hold
35
– – ﹤0.01% 428
2022
Q2 		$2.13K Hold
35
– – ﹤0.01% 489
2022
Q1 		$2.2K Hold
35
– – ﹤0.01% 481
2021
Q4 		$2.65K Buy
+35
New +$3.06K ﹤0.01% 496

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

West Paces Advisors's CRSP Position: Q2 2026 in Review

West Paces Advisors opened a new position in CRISPR Therapeutics (CRSP) in Q2 2026: 153 shares worth $8.35K. The stake represents ﹤0.01% of the portfolio and ranks #398 among its holdings. This is a return to the name: West Paces Advisors previously reported a position in CRSP as recently as Q1 2025.

West Paces Advisors first reported a position in CRSP in Q4 2021 and has held it in 15 quarters since. 524 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • West Paces Advisors held 153 shares of CRISPR Therapeutics worth $8.35K as of Q2 2026.
  • CRISPR Therapeutics was a new West Paces Advisors position in Q2 2026.
  • CRISPR Therapeutics made up ﹤0.01% of West Paces Advisors's portfolio in Q2 2026, its #398 holding.
  • West Paces Advisors first reported a position in CRISPR Therapeutics in Q4 2021 and has held it in 15 quarters since.
  • 524 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on West Paces Advisors's 13F filing for Q2 2026, filed 20 Jul 2026.